In the News
Diet replacement can lead to diabetes remission in real-world settings, study finds
A diet intervention from the National Health Service in England resulted in 27% of participating type 2 diabetes patients achieving remission, with mean weight loss of 14.8 kg, and even better results among patients who finished the year-long program.
Inpatients on insulin effectively used personal CGMs during hospitalization
Most patients and nurses reported satisfaction with a protocol that allowed use of personal continuous glucose monitors (CGMs) in lieu of fingerstick blood glucose tests, a retrospective single-center study reported.
Hyperkalemia may be less common with GLP-1s than DPP-4s
Patients with type 2 diabetes who were taking glucagon-like peptide-1 (GLP-1) receptor agonists had lower rates of hyperkalemia than those taking dipeptidyl peptidase-4 (DPP-4) inhibitors and were more likely to continue renin-angiotensin system inhibitors over the long term, a cohort study found.
MKSAP quiz: Hypoglycemia from insulin error
This month's quiz asks readers to evaluate a 22-year-old woman with a recent type 1 diabetes diagnosis who has called about anxiety, shakiness, and sweating. She reports accidentally taking 18 units of insulin aspart before bedtime, rather than the prescribed basal insulin, insulin glargine.
Spotlight on GLP-1 receptor agonists and suicidality
Several recent studies did not find an association between glucagon-like peptide-1 (GLP-1) receptor agonists and suicidality, but one analysis identified a potential risk in patients with mental health issues before starting semaglutide.
Little difference in dementia risk with SGLT-2s vs. dulaglutide
Older patients with type 2 diabetes starting sodium-glucose cotransporter-2 (SGLT-2) inhibitors had an estimated difference of less than a percentage point in five-year risk of clinical onset of dementia compared with those starting the glucagon-like peptide-1 receptor agonist dulaglutide, a South Korean study found.
Medicare coverage of semaglutide would be costly
Covering semaglutide for patients who are overweight and have cardiovascular disease could cost Medicare an additional $34 to $145 billion annually, researchers estimated.
In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y
A recent industry-funded trial solidifies glucagon-like peptide-1 receptor agonists as a treatment for patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD), but questions about safety in patients with advanced CKD remain, an ACP Journal Club commentary said.
Case report of DKA from a gout flare
A recently published case described a patient with a history of tophaceous gout who developed diabetic ketoacidosis (DKA) during a severe acute polyarticular gout flare.